07-06-2017
16-02-2020
18-08-2016
1133448
1703 7
Code 1295
- 1 -
PRESCRIBING INFORMATION
CONDYLOX
solution
1.
NAME OF THE MEDICINAL PRODUCT
CONDYLOX 0.5% solution for external application
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1ml contains:
Podophyllotoxin 5mg
in buffered ethanol solution.
For a full list of other excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Clear colourless solution for application on the skin
4.
CLINICAL PARTICULARS
4.1 Therapeutic indications
Treatment of external genital warts (Condylomata Acuminatum).
4.2
Posology, method and duration of administration
Treatment is carried out twice daily (at an interval of 12 hours) on three consecutive days. Then a
treatment-free interval of four days should be observed. Therapy should be repeated until the
condylomata disappear; the maximum duration of administration is four weeks.
If no success in treatment can be achieved after four treatment cycles, a different from of therapy
must be chosen.
Prior to application, the body parts to be treated must be washed carefully with water and soap
and subsequently dried with caution. The solution is applied with a cotton tipped applicator on
the condylomata. The cotton pad may be used only once!
Take care that podophyllotoxin does not reach the surrounding healthy skin and/or mucosa.
Condylox should not be applied to non-genital warts.
After application, let it dry for a few minutes.
Condylox 0.5% solution is left at the site of application and must not be washed off again. The
treated spots must have dried before coming in contact with clothing.
After each treatment hands should be cleaned thoroughly.
- 2 -
Therapy with Condylox 0.5% solution may be carried out at home by the patients themselves.
However, lesions in the female and lesions greater than 4cm² in the male should be treated under
direct medical supervision.
Children
Condylox 0.5% solution is contraindicated in children under the age of 12 (See Section 4.3).
4.3
Contraindications
Over- sensibility to podophyllotoxin or another excipient of Condylox 0.5% solution.
Inflamed or bleeding pointed condylomata, or open wounds following surgical procedures.
Simultaneous administration of other preparations containing podophylline.
Pregnancy and lactation.
Children under the age of 12.
4.4
Special warnings and precautions for use
There are no data available on the administration of Condylox 0.5% solution in young adults
between 12 and 18 years.
Condylox 0.5% must not come in contact with the eyes. However, if podophyllotoxin gets into
the eye, immediate rinsing with water should be carried out and a doctor should be consulted.
Condylox 0.5% is exclusively used for the therapy of condylomata and must not be applied to
other warts or naevi. Contact with healthy skin is to be avoided.
Lesions in the female and lesions greater than 4 cm2 in the male should be treated under direct
medical supervision.
Male patients should wear condoms until healed completely. The partners should be requested to
have themselves examined by a doctor.
4.5
Interactions with other medicinal products and other forms of interaction
Simultaneous treatment with other preparations containing podophylline should be avoided,
since these also contain podophyllotoxin.
4.6
Pregnancy and lactation
Condylox 0.5% solution causes serious damage to the unborn child if used during pregnancy.
Condylox 0.5% solution is contraindicated during pregnancy and lactation (see 4.3)
4.7
Effects on ability to drive and use machines
Condylox 0.5% solution has no or negligible influence on the ability to drive and the ability to
use machines
- 3 -
4.8
Side effects
Disorders of the reproductive system and breast:
Podophyllotoxin may induce balanoposthitis
Skin and subcutaneous
tissue disorders:
Local irritation symptoms of the area treated such as itching, burning.
Phimoses, erosions and ulcerations have been observed.
The frequency of these side effects is unknown.
4.9 Overdosage
The risk of systemic toxicity after topical administration is increased with large-area treatment
using excessive quantities for a longer period, or when treating bleeding or recently eliminated
pointed condylomata, and with unintentional administration on intact skin or mucosa.
Symptoms include nausea, vomiting, abdominal pain and diarrhoea; thrombocytopenia,
leukopenia, hepatotoxicity or renal failure may occur. CNS-related adverse events are delayed in
onset and prolonged in duration and include acute psychotic reactions, hallucinations, confusion,
dizziness, stupor, ataxia, hypotonia, seizures and coma. Peripheral and autonomic neuropathies
develop later and may result in paraesthesias, reduced reflexes, muscle weakness, tachycardia,
apnoea, orthostatic hypotension, paralytic ileus and urinary retention.
After topical overdosage the skin is to be cleaned thoroughly with soap and water, Eyes are to be
rinsed thoroughly with water
or if available, with an appropriate eye-cleaning solution. If accidentally
ingested, give stomach washout and monitor electrolyte balance, blood gases, liver function and blood
picture.
5.
PHARMACOLOGICAL PROPERTIES
5.1
Pharmacodynamic properties
Pharmacotherapeutic group: chemotherapeutic agent for topical administration, antiviral agent
ATC-code: D06BB04
Podophyllotoxin is the therapeutically active constituent of podophylline, the resin extracted
from the rootstock of pododphyllum species (berberidaceae).
Podophyllotoxin has a clearly antimitotic effect. Due to the attachment to tubeline, the formation
of microtubuli and thus the formation of spindles in the metaphasis of cell division is impeded. A
necrosis of the wart tissue is triggered as a consequence of the blocked cell division.
It is also caustic to normal skin if applied to it and can be absorbed into the systemic circulation with
resultant toxic effects, in particular nausea, vomiting and thrombocytopenia.
In addition, podophyllotoxin has a tumor destructing and anti-inflammatory effect.
5.2
Pharmacokinetic properties
- 4 -
Absorption
Since
podophyllotoxin with local administration is absorbed only to a minor degree, systemic
effects are not to be expected during the recommended administration and dosage. The
quantity absorbed of topically applied podophyllotoxin depends on the volume of application.
Quantities up to 50µl and 0.5% ethanol solution (corresponding to Condylox) could not be
verified in the serum. Patients treated with 100-1500µl showed serum peak values of 1-
17ng/ml within 1 to 2 hours. There was no cumulation of the substance in the serum.
The administration of up to 250µl twice daily for three days is to be considered safe and does not
lead to systemic toxicity.
Distribution
Owing to its high lipid solubility, it is distributed through the body including the CNS.
Metabolism
No data are available on the metabolism of podophyllotoxin.
Elimination
The half-life of podophyllotoxin is 1 – 4.5 hours.
5.3
Preclinical safety data
The LD
of Condylox 0.5% in mice is 33 mg.kg
and in rats is 15 mg.kg
. In both species, therapy
produced an acute leukopenia. As a cytotoxic agent it has teratogenic potential and has been associated
with intrauterine deaths in mice and rats.
6.
PHARMACEUTICAL PARTICULARS
6.1
List of excipients
Sodium lactate
Lactic acid
Ethanol 96%
6.2
Incompatibilities
Not applicable
6.3
Shelf life
Two years. Shelf life after first opening
:
6 weeks
or expiry date whichever comes first.
6.4
Special precautions for storage
Do not store above 25°C. Light protection required.
- 5 -
6.5
Nature and contents of container
The amber glass vial with child-proof screw top made of polypropylene contains a 3.5ml
solution. The pack is supplied with disposable plastic applicators which have a small hole in one
end that holds the solution.
6.6
Special precautions for disposal and other handling instructions
Unused pharmaceutical products or waste material must be disposed of in accordance with local
requirements.
Condylox 0.5% Solution is flammable and should be kept away from naked flames.
A patient information leaflet is provided with the product giving details on the use and handling
of the product.
Manufacturer:
Takeda Austria GmbH, Linz, Austria
License Holder:
Takeda Israel Ltd., 25 Efal St., POB 4140, Petach - Tikva 4951125
The format of this leaflet was determined by the Ministry of Health and its content was
checked and approved in February 2014.
העדוה העדוה
לע לע
הרמחה הרמחה
(
(
עדימ עדימ
ןולעב )תוחיטב ןולעב )תוחיטב
ןכרצל ןכרצל
ןכדועמ( ןכדועמ(
05.2013
05.2013
ךיראת
19.01.14
םש
רישכת
תילגנאב
רפסמו
םושירה
Condylox 5014.26541
םש
לעב
םושירה
וגירפ
לארשי
תויונכוס
מ"עב
ספוט
הז
דעוימ
טורפל
תורמחהה
דבלב
תורמחהה
תושקובמה
קרפ
ןולעב טסקט
יחכונ טסקט
שדח ינפל שומישה
הפורתב יתמ
ןיא
שמתשהל
?רישכתב לא
ישמתשת
רישכתב
רשאכ
ךניה
ןוירהב וא
.הקינמ
ןיא
שמתשהל
םא
העודי תושיגר
דחאל
יביכרממ
.רישכתה ןיא
שמתשהל
לע
רוע
םמדמ
וא
יתקלד
וא לע
םיעצפ
םיחותפ
ורבעש
לופיט
.יגרוריכ רישכתה
וניא
דעוימ
םידליל
תחתמ
ליגל
ןיא .
שמתשהל
דחיב
םע
רישכת
ףסונ ליכמה
Podophyllotoxin
ןיא
שמתשהל
תב הפור
:םא
תא
ןוירהב
וא
הקינימ
העודי
תושיגר
דחאל
יביכרממ
תה .רישכ
ןיא
שמתשהל
לע
רוע
םמדמ
וא
יתקלד
וא לע
םיעצפ
םיחותפ
ורבעש
לופיט
.יגרוריכ
רישכתה
וניא
דעוימ
םידליל
תחתמ
ליגל
ןיא
שמתשהל
דחיב
םע
רישכת
ףסונ
ליכמה
Podophyllotoxin
ןיא
שמתשהל
רישכתב
לע
רוע
םייניע ,אירב וא
לע
םינפה
רחאמ
לוכיו
םרגהל
יוריג רומח
תורהזא תודחוימ תועגונה שומישל
:
הפורתב :תורהזא םא
ךניה
ה/שיגר
ןוזמל
והשלכ
וא
הפורתל ךילע ,יהשלכ
עידוהל
ךכ-לע
אפורל
ינפל שומישה
.רישכתב שי
ענמיהל
עגממ
רישכתה
םע
רוע
,אירב תויריר
.םייניעהו הרקמב
לש
עגמ
םע
שי ,םייניעה
ףוטשל ןתוא
תומכב
הלודג
לש
םימ
ץעייתהלו
םע שי .אפורה
ענמיהל
תחירממ
הפורתה
לע םיחטש
ןיא .םיבחרנ
שמתשהל
רישכתב לופיטל
תולביב
גוסמ
רחא
וא
שי .תומושב ענמיהל
ןוירהמ
ןמזב
לופיטה
,סקולידנוקב רחאמ
העפשההש
לע
רבועה
הניא
.העודי ןיא
תותשל
תוניי
וא
תואקשמ
םיפירח תפוקתב
.לופיטה תורהזא
תודחוימ
תועגונה
שומישל :הפורתב
ינפל
לופיטה
רפס ,סקולידנוקב אפורל
:םא םא
ךניה
שיגר
ןוזמל
והשלכ
וא
הפורתל .יהשלכ
שי
ענמיהל
עגממ
הפורתה
םע
רוע
,אירב תויריר
הרקמב .םייניעהו
לש
עגמ
םע שי ,םייניעה
ףוטשל
ןתוא
תומכב
הלודג
לש םימ
ץעייתהלו
םע
.אפורה
שי
ענמיהל
תחירממ
הפורתה
לע
םיחטש .םיבחרנ
שי -םישנל
שמתשהל
הפורתב
תחת
החגשה תיאופר
.הדומצ
םא -םירבגל
ךניה
לבוס
תולבימ
,תובר ערתשמה תו
לע
חטש
לוד
,מ"ס שי
שמתשהל
הפורתב
תחת
החגשה תיאופר
הדומצ
ןיא
שמתשהל
הפורתב
לופיטל
תולביב
גוסמ רחא
וא
.תומושב שי
ענמיהל
ןוירהמ
ןמזב
לופיטה רחאמ ,סקולידנוקב
העפשההש
לע רבועה
הניא
.העודי ןוירה
הקנהו
ןיא
שמתשהל
סקולידנוקב
םא
תא
,ןוירהב הסנמ
תורהל
וא
.הקינימ שומיש :ןונימ דציכ
שמתשת
:
הפורתב ןונימ
יפל
תוארוה
אפורה
.דבלב
ןיא רובעל
לע
הנמה
.תצלמומה םירבגל לופיטל -
ימצע
תיבב
םאתהב תוארוהל
ןונימה ,אפורה
ץלמומה
:אוה םיימעפ
רקובב ,םויב
ברעבו
לדבהב
לש
ךשמב ,תועש
השולש
םימי
.םיפוצר םישנל
לופיטל -
י"ע
אפורה
,ותאפרמב
ןונימה
ץלמומה
םעפ :אוה
םויב
ךשמב השולש
םימי
.םיפוצר שי
תוכחל
האפרמב
דע
רמוחהש
שבייתי .ירמגל לופיטה
םירבגל
םישנלו
לוכי
שדחתהל
ידמ עובש
דע
םומיסקמל
לש
תועובש םיפוצר
עובש(
לופיטה
בכרומ
ימי םאתהב ,לופיט
-ו ,תויחנהל
ימי
.)החונמ י/םיש
בל
אל
הפורת !עולבל
וז
תדעוימ שומישל
ינוציח
.דבלב ןפוא
:שומישה ינפל
תליחת
שי ,לופיטה
ףוטשל
בטיה
תא רוזיאה
עוגנה
ןובסב
םימו
שביילו
שי .בטיה חורמל
תא
רמוחה
תועצמאב
ןולקמה תיתדוקנ ,קייודמב
לע
רהזיהל ,תלביה רמוחהש
אל
אובי
עגמב
םע
רוע
אירב אדוולו
רחאלש
שומישה
קובקבה
רוגס ןיא .בטיה
שמתשהל
ותואב
ןולקמ
רתוי םעפמ
רחאל .תחא
החירמה
שי
תתל רמוחל
שבייתהל
ךשמב
רפסמ
ינפל ,תוקד ואוב
עגמב
םע
שי .םידגבה
דיפקהל ףוטשל
בטיה
םיידי
םימב
ןובסו
רחאל
לכ שומיש
.סקולידנוקב דציכ
י/לכות
עייסל
תחלצהל
?לופיטה ךילע
םילשהל
תא
לופיטה
ץלמוהש
די-לע
.אפורה םג
םא
לח
רופיש
בצמב
ךתואירב
ןיא קיספהל
לופיטה
רישכתב
אלל
תוצעייתה םע
.אפור תולבי
ירבאב
ןימה
ןה
שי ,ןכל .תוקבדמ חיטבהל
תב/ןבש
גוזה
וקדבי
י"ע
.אפורה שי
שמתשהל
םודנוקב
יעצמאכ
ןגמ
ינפמ תקבדה
תב/ןב
גוזה
דע
יופירל
.טלחומ
דימת
שי
שמתשהל
יפל
תוארוה
.אפורה
ךילע קודבל
םע
אפורה
וא
חקורה
םא
ךניא
.חוטב ןונימה
ןפואו
לופיטה
ועבקי
לע
ידי
אפורה
דבלב
ןונימה
לבוקמה ךרדב
ללכ
:אוה םירבגל לופיטל -
ימצע
תיבב
םאתהב
תוארוהל ןונימה ,אפורה
םיימעפ :ץלמומה
רקובב ,םויב ברעבו
לדבהב
לש
ךשמב ,תועש
השולש םימי
.םיפוצר םישנל
לופיטל -
י"ע
אפורה
,ותאפרמב ןונימה
םעפ :ץלמומה
םויב
ךשמב השולש
םימי
שי .םיפוצר
תוכחל
האפרמב
דע רמוחהש
שבייתי
.ירמגל ןיא
רובעל
לע
הנמה
תצלמומה
.
םיש
בל
:
ןיא
הפורת !עולבל
וז
תדעוימ שומישל
ינוציח
.דבלב ינפל
תליחת
שי ,לופיטה
ףוטשל
בטיה
תא רוזיאה
עוגנה
ןובסב
םימו
שביילו
שי .בטיה חורמל
תא
רמוחה
תועצמאב
ןולקמה
,קייודמב תיתדוקנ
לע
רהזיהל ,תלביה
רמוחהש
אל
אובי עגמב
םע
רוע
אירב
אדוולו
רחאלש
שומישה קובקבה
רוגס
ןיא .בטיה
שמתשהל
ותואב ןולקמ
רתוי
םעפמ
רחאל .תחא
החירמה
שי תתל
רמוחל
שבייתהל
ךשמב
רפסמ
,תוקד ינפל
ואוב
עגמב
םע
שי .םידגבה
דיפקהל ףוטשל
בטיה
םיידי
םימב
ןובסו
רחאל
לכ
שומיש .סקולידנוקב לופיטה
םירבגל
םישנלו
לוכי
שדחתהל
ידמ עובש
דע
םומיסקמל
לש
תועובש
םיפוצר עובש(
לופיטה
בכרומ
ימי
םאתהב ,לופיט -ו ,תויחנהל
ימי
.)החונמ םא
תלטנ
תועטב
ןונימ
רתי
וא
םא
תועטב
עלב דלי
ןמ
הפורתה
הנפ
דימ
אפורל
וא
רדחל ןוימ
לש
תיב
םילוח
אבהו
תזירא
הפורתה .ךתיא םא
תחכש
שמתשהל
סקולידנוקב
ןמזב
,שורדה שי
חורמל
תא
הפורתה
עגרב
םא .תרכזנש
ןמז הנמה
האבה
גלד ,ברקתמ
לע
לופיטה תרסחהש
ךשמהו
שמתשהל
יפל
תוארוה .אפורה שי
דימתהל
לופיטב
יפכ
ץלמוהש
לע
ידי
.אפורה םג
םא
לח
רופיש
בצמב
ךתואירב
ןיא
קיספהל לופיטה
רישכתב
אלל
תוצעייתה
םע
.אפור תולבי
ירבאב
ןימה
ןה
שי ,ןכל .תוקבדמ חיטבהל
תב/ןבש
גוזה
וקדבי
י"ע
.אפורה שי
שמתשהל
םודנוקב
יעצמאכ
ןגמ
ינפמ תקבדה
תב/ןב
גוזה
דע
יופירל
.טלחומ םא
שי
ךל
תולאש
תופסונ
עגונב
שומישל ץעוויה ,הפורתב
אפורב
וא
.חקורב ב"צמ
ובש ,ןולעה
נמוסמ תו
תורמחהה
תושקובמה
לע
עקר
בוהצ
םייוניש
םניאש
רדגב
תורמחה
ונמוס
ןולעב עבצב )
שי .הנוש
ןמסל
קר
ןכות
יתוהמ
אלו
םייוניש םוקימב
.טסקטה רבעוה
ראודב
ינורטקלא
ךיראתב
19.01.14
העדוה העדוה
לע לע
הרמחה הרמחה
(
(
עדימ עדימ
ןולעב )תוחיטב ןולעב )תוחיטב
ל
ל
אפור אפור ןכדועמ( ןכדועמ(
05.2013
05.2013
ךיראת
19.01.14
םש
רישכת
תילגנאב
רפסמו
םושירה
Condylox 5014.26541
םש
לעב
םושירה
וגירפ
לארשי
תויונכוס
מ"עב
ספוט
הז
דעוימ
טורפל
תורמחהה
דבלב
תורמחהה
תושקובמה קרפ
ןולעב טסקט
יחכונ טסקט
שדח
Posology, method
and duration of
administration
Treatment is carried out twice
daily (at an interval of 12 hours)
on three consecutive days. Then a
treatment-free interval of four
days should be observed. Therapy
should be repeated until the
condylomata disappear; the
maximum duration of
administration is four weeks.
If no success in treatment can be
achieved after four treatment
cycles, a different from of therapy
must be chosen.
Prior to application, the body
parts to be treated must be washed
carefully with water and soap and
subsequently dried with caution.
The solution is applied with a
cotton tipped applicator on the
condylomata. The cotton pad may
be used only once!
Take care that podophyllotoxine
does not reach the surrounding
healthy skin and/or mucosa.
Condylox should not be applied to
other warts.
After application, let it dry for a
few minutes.
Treatment is carried out twice daily (at an
interval of 12 hours) on three consecutive days.
Then a treatment-free interval of four days
should be observed. Therapy should be
repeated until the condylomata disappear; the
maximum duration of administration is four
weeks.
If no success in treatment can be achieved after
four treatment cycles, a different from of
therapy must be chosen.
Prior to application, the body parts to be treated
must be washed carefully with water and soap
and subsequently dried with caution. The
solution is applied with a cotton tipped
applicator on the condylomata. The cotton pad
may be used only once!
Take care that podophyllotoxin does not reach
the surrounding healthy skin and/or mucosa.
Condylox should not be applied to other non-
genital warts.
After application, let it dry for a few minutes.
Condylox 0.5% solution is left at the site of
application and must not be washed off again.
The treated spots must have dried before
coming in contact with clothing.
After each treatment hands should be cleaned
thoroughly.
Condylox 0.5% solution is left at
the site of application and must
not be washed off again. The
treated spots must have dried
before coming in contact with
clothing.
After each treatment hands should
be cleaned thoroughly.
Therapy with Condylox 0.5%
solution may be carried out at
home by the patients themselves.
However, lesions in the female
and lesions greater than 4cm² in
the male should be treated under
direct medical supervision.
Condylox 0.5% solution is
contraindicated in children under
the age of 12 (See Section 4.3).
Therapy with Condylox 0.5% solution may be
carried out at home by the patients themselves.
However, lesions in the female and lesions
greater than 4cm² in the male should be treated
under direct medical supervision.
Children
Condylox 0.5% solution is contraindicated in
children under the age of 12 (See Section 4.3).
Contraindications
Over- sensibility to
podophyllotoxine or another
excipient of Condylox 0.5%
solution
Inflamed or bleeding pointed
condylomata
Simultaneous administration of
other preparations containing
podophylline
Pregnancy and lactation.
Children under the age of 12
Over- sensibility to podophyllotoxin or another
excipient of Condylox 0.5% solution.
Inflamed or bleeding pointed condylomata, or
open wounds following surgical procedures.
Simultaneous administration of other
preparations containing podophylline.
Pregnancy and lactation.
Children under the age of 12.
Special warnings
and precautions for
use
There are no data available on the
administration of Condylox 0.5%
solution in young adults between
12 and 18 years.
Condylox 0.5% must not come in
contact with the eyes. However, if
podophyllotoxine gets into the
eye, immediate rinsing with water
should be carried out and a doctor
should be consulted.
Condylox 0.5% is exclusively
used for the therapy of
condylomata and must not be
applied to other warts or naevi.
Contact with healthy skin is to be
avoided.
Alcohol consumption is to be
avoided during treatment. The
There are no data available on the
administration of Condylox 0.5% solution in
young adults between 12 and 18 years.
Condylox 0.5% must not come in contact with
the eyes. However, if podophyllotoxin gets into
the eye, immediate rinsing with water should be
carried out and a doctor should be consulted.
Condylox 0.5% is exclusively used for the
therapy of condylomata and must not be
applied to other warts or naevi. Contact with
healthy skin is to be avoided.
Lesions in the female and lesions greater than 4 cm
in the male should be treated under direct medical
supervision.
Alcohol consumption is to be avoided during
treatment. The ingestion of alcohol during
therapy may lead to massive increase of
ingestion of alcohol during
therapy may lead to massive
increase of undesired effects.
Male patients should wear
condoms until healed completely.
The partners should be requested
to have themselves examined by a
doctor.
undesired effects.
Male patients should wear condoms until
healed completely. The partners should be
requested to have themselves examined by a
doctor.
Overdosage
The risk of systemic toxicity after
topical administration is increased
with large-area treatment using
excessive quantities for a longer
period, or when treating bleeding
or recently eliminated pointed
condylomata, and with
unintentional administration on
intact skin or mucosa.
After topical overdosage the skin
is to be cleaned thoroughly with
soap and water, Eyes are to be
rinsed thoroughly with water.
The risk of systemic toxicity after topical
administration is increased with large-area
treatment using excessive quantities for a
longer period, or when treating bleeding or
recently eliminated pointed condylomata, and
with unintentional administration on intact skin
or mucosa.
Symptoms include nausea, vomiting,
abdominal pain and diarrhoea;
thrombocytopenia, leukopenia, hepatotoxicity
or renal failure may occur. CNS-related
adverse events are delayed in onset and
prolonged in duration and include acute
psychotic reactions, hallucinations, confusion,
dizziness, stupor, ataxia, hypotonia, seizures
and coma. Peripheral and autonomic
neuropathies develop later and may result in
paraesthesias, reduced reflexes, muscle
weakness, tachycardia, apnoea, orthostatic
hypotension, paralytic ileus and urinary
retention.
After topical overdosage the skin is to be
cleaned thoroughly with soap and water,
Eyes are to be rinsed thoroughly with
water
or if available, with an appropriate
eye-cleaning
solution.
accidentally
ingested, give stomach washout and monitor
electrolyte
balance,
blood
gases,
liver
function and blood picture.
Pharmacodynamic
properties
Pharmacotherapeutic group:
chemotherapeutic agent for
topical administration, antiviral
agent
ATC-code: D06BB04
Podophyllotoxine is the
therapeutically active constituent
of podophylline, the resin
extracted from the rootstock of
pododphyllum species
(berberidaceae).
Pharmacotherapeutic group: chemotherapeutic
agent for topical administration, antiviral agent
ATC-code: D06BB04
Podophyllotoxin is the therapeutically active
constituent of podophylline, the resin extracted
from the rootstock of pododphyllum species
(berberidaceae).
Podophyllotoxin has a clearly antimitotic
effect. Due to the attachment to tubeline, the
formation of microtubuli and thus the formation
of spindles in the metaphasis of cell division is
Podophyllotoxine has a clearly
antimitotic effect. Due to the
attachment to tubeline, the
formation of microtubuli and thus
the formation of spindles in the
metaphasis of cell division is
impeded. A necrosis of the wart
tissue is triggered as a
consequence of the blocked cell
division.
In addition, podophyllotoxine has
a tumor destructing and anti-
inflammatory effect.
impeded. A necrosis of the wart tissue is
triggered as a consequence of the blocked cell
division.
It is also caustic to normal skin if applied to it and
can be absorbed into the systemic circulation with
resultant toxic effects, in particular nausea,
vomiting and thrombocytopenia.
In addition, podophyllotoxin has a tumor
destructing and anti-inflammatory effect.
Pharmacokinetic
properties
Since podophyllotoxine with local
administration is absorbed only to
a minor degree, systemic effects
are not to be expected during the
recommended administration and
dosage. The quantity absorbed of
topically applied
podophyllotoxine depends on the
volume of application. Quantities
up to 50µl and 0.5% ethanol
solution (corresponding to
Condylox) could not be verified in
the serum. Patients treated with
100-1500µl showed serum peak
values of 1-17ng/ml within 1 to 2
hours. There was no cumulation
of the substance in the serum. The
half-life of podophyllotoxine is 1
– 4.5 hours.
The administration of up to 250µl
twice daily for three days is to be
considered safe and does not lead
to systemic toxicity.
Absorption
Since podophyllotoxin with local
administration is absorbed only to a minor
degree, systemic effects are not to be
expected during the recommended
administration and dosage. The quantity
absorbed of topically applied
podophyllotoxin depends on the volume of
application. Quantities up to 50µl and 0.5%
ethanol solution (corresponding to
Condylox) could not be verified in the
serum. Patients treated with 100-1500µl
showed serum peak values of 1-17ng/ml
within 1 to 2 hours. There was no
cumulation of the substance in the serum
The administration of up to 250µl twice daily
for three days is to be considered safe and does
not lead to systemic toxicity.
Distribution
Owing to its high lipid solubility, it is distributed
through the body including the CNS.
Metabolism
No data are available on the metabolism of
podophyllotoxin.
Elimination
The half-life of podophyllotoxin is 1 – 4.5
hours.
Preclinical safety
data
Preclinical data for the active
substance podophyllotoxine are
not known. Due to many years of
clinical experience, however, no
other undesired effects are to be
expected than those described in
other sections of the summary of
Preclinical data for the active substance
podophyllotoxin are not known. Due to many
years of clinical experience, however, no other
undesired effects are to be expected than those
described in other sections of the summary of
product characteristics.
The LD
of Condylox 0.5% in mice is 33 mg.kg
product characteristics.
and in rats is 15 mg.kg
. In both species, therapy
produced an acute leukopenia. As a cytotoxic agent
it has teratogenic potential and has been associated
with intrauterine deaths in mice and rats.
ב"צמ
ובש ,ןולעה
נמוסמ תו
תורמחהה
שקובמה תו
לע
עקר
.בוהצ םייוניש
םניאש
רדגב
תורמחה
ונמוס
)ןולעב( עבצב
שי .הנוש
ןמסל
קר
ןכות
יתוהמ
אלו
םייוניש םוקימב
.טסקטה רבעוה
ראודב
ינורטקלא
ךיראתב
19.01.14